Promoted to Head of US Marketing for Porton USA / J-Star Research for Drug Substance and Drug Product business units to lead our regional marketing team on marketing strategy, trade show, content development and digital marketing campaigns while supporting Porton's global marketing objectives. In addition, continuing as the Executive Director Business Development for Drug Product, I support all new drug product development opportunities coming into Porton USA / J-Star Research for early stage development across all dosage forms and GMP clinical manufacturing for oral solid dose, sterile liquid/lyo and non-sterile liquids and semi solid products. With the ability to leverage Porton Pharma Solutions global network of API and Drug Product manufacturing alongside the strong history with innovator drug development by Porton USA / J-Star Research, we have supported numerous biotech companies as well as 17 of the top 20 pharmaceutical companies to deliver world class solutions for the most complex drug development challenges.

Global responsibility for bringing new drug product development opportunities into Porton USA / J-Star Research for early stage development across all dosage forms and GMP clinical manufacturing for non-sterile oral solid dose, liquids, and semi solid products. With the ability to leverage Porton Pharma Solutions global network of API and Drug Product manufacturing alongside the Porton USA (J-Star Research) strong history of innovator drug development with 17 of the top 20 pharmaceutical companies to deliver world class solutions to your most complex drug development challenges.

Helping lead and guide the ISPE Great Lakes Chapter as we grow our membership and extend our outreach to the pharmaceutical engineering community.

Part of the Cambrex small molecule drug product team with responsibility for growing commercial sales at the Whippany, NJ and Mirabel, Quebec manufacturing sites. Helping our clients bring NDA, ANDA, and OTC oral solid tablets and capsules, oral liquids, and topical creams, gels, and sterile/non-sterile ointments through commercial launch.

Leading and developing AST's sales and business development team to support our growth in 2021.

AST is a privately held company that revolutionized the cGMP aseptic small batch fill/finish industry with the ASEPTiCell® over 10 years ago. Using robotics and advanced automation, this system was the industry’s first multi-format cGMP aseptic fill/finish machine capable of processing ready-to-use vials, syringes and cartridges using a single machine. Today AST is recognized as an industry leader in flexible aseptic filling and offers an extensive range of products that support drug product development, clinical and commercial needs using AST’s GENiSYS® Lab, GENiSYS® C, GENiSYS® R, and ASEPTiCell® product lines.

Director of Business Development supporting Frontida's development and commercial manufacturing using proprietary controlled release technologies for NDA and ANDA oral dose products. With development and manufacturing capabilities at both the Philadelphia PA and Aurora IL sites along with the ability to support DEA scheduled products, Frontida Biopharm can be your trusted partner.

Head of business development for Denison Pharmaceuticals, a leading liquid and semisolid OTC and consumer healthcare products based in Lincoln, RI. Responsible for identifying, qualifying, and securing new commercial manufacturing and packaging opportunities.

Ei is a full service contract developer, manufacturer, and packager of Rx, OTC, and therapeutic skin care products. We operate a cGMP facility near Charlotte, NC.

Eurofins-AvTech is an FDA registered pharmaceutical analytical and stability contract service provider. We can provide expert method development and trouble-shooting as well as routing product and chemical testing, investigation, and stability services.

(formerly known as Cardinal Health)Sales/Business Development of contract manufacturing and packaging services

Sales of contract manufacturing and packaging services